N-Acetyl Selank

Typical use cases

Dosing guidelines

Titration

Community protocols typically describe starting at the lower end and using the peptide in short courses (commonly ~14 days) followed by a washout period of 1-3 weeks; framed neutrally as reported practice, not guidance

Reconstitution

Nasal spray: lyophilized powder reconstituted with sterile/bacteriostatic water (or saline) and dispensed via a metered nasal applicator. Injectable form: lyophilized powder reconstituted with bacteriostatic water before subcutaneous use.

Injection sites

Primarily intranasal (sprayed/dropped into the nostrils); a subcutaneous injectable form (e.g., abdomen) is also reported

Storage & handling

Lyophilized powder stored frozen or refrigerated; once reconstituted, kept refrigerated at 2-8°C (36-46°F) and protected from light

Side effects

• Nasal dryness or irritation Mild · Common
• Throat irritation or postnasal drip Mild · Uncommon
• Drowsiness or fatigue Mild · Uncommon
• Headache Mild · Uncommon
• Injection-site reactions (pain, redness, swelling) when injected Mild · Uncommon
• Hypersensitivity / allergic reaction Moderate · Rare

Research summary

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide derived from the immunomodulatory tetrapeptide tuftsin, developed in Russia as a non-benzodiazepine anxiolytic; N-Acetyl Selank Amidate is a second-generation analog bearing N-terminal acetylation and C-terminal amidation intended to block amino/carboxypeptidase degradation and extend stability. The bulk of the published evidence concerns the parent Selank rather than the acetylated/amidated form specifically, so claims about the modified peptide are largely extrapolated. A 2008 randomized comparative clinical trial (Zozulia et al., n=62) reported that intranasal Selank produced anxiolytic effects comparable to the benzodiazepine medazepam in generalized anxiety disorder and neurasthenia, with additional antiasthenic effects, less sedation, and no withdrawal on discontinuation. Preclinical work indicates Selank does not directly alter GABAergic gene expression in neuroblastoma cells but appears to modulate GABA-related signaling indirectly, influences enkephalin and monoamine metabolism, and upregulates hippocampal BDNF expression in rats; a rat study also found it enhanced the anxiolytic effect of diazepam under chronic mild stress. Limitations are substantial: most human data come from a small number of Russian-language studies that are difficult to independently verify, there are essentially no rigorous trials of the N-acetyl-amidated analog, long-term safety data are lacking, and the compound is not FDA-approved and is sold for laboratory research use only. Reported molecular weight and half-life figures for the acetylated/amidated form are sparse and not authoritatively published. Overall the peptide is biologically plausible and reported as well tolerated, but the evidence base is thin by Western clinical standards.

Key references

• https://pubmed.ncbi.nlm.nih.gov/18454096/
• https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2017.00089/full
• https://pmc.ncbi.nlm.nih.gov/articles/PMC4757669/
• https://doi.org/10.1134/S0012496608040066
• https://onlinelibrary.wiley.com/doi/10.1155/2017/5091027

Related compounds